Zydus Lifesciences Scores USFDA Nod for Hypertension Treatment Medication

Zydus Lifesciences Limited (Zydus), a leading Indian multinational pharmaceutical company, announced a significant development in its quest to expand its global reach. The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone Tablets, 40 mg/12.5 mg and 40 mg/25 mg, under the brand name Edarbyclor®.

Addressing High Blood Pressure

This medication is a combination of Azilsartan Medoxomil, an angiotensin II receptor blocker (ARB), and Chlorthalidone, a thiazide-like diuretic. The combined action of these two drugs helps to lower blood pressure in patients suffering from hypertension. Zydus highlights the importance of this medication, considering the prevalence of high blood pressure as a global health concern.

Manufacturing and Market Potential

The approved tablets will be manufactured at Zydus’ formulation manufacturing facility situated in the Ahmedabad SEZ – II, India. According to IQVIA MAT March 2024 data, Azilsartan Medoxomil and Chlorthalidone Tablets boast an existing annual sales value of USD 77.9 million in the United States alone, indicating a substantial market opportunity for Zydus.

A Legacy of Innovation

This USFDA approval marks a significant milestone for Zydus, solidifying its position as a leader in the development and manufacturing of high-quality generic medications. With this latest approval, Zydus’ portfolio now boasts a total of 397 USFDA approvals, a testament to its ongoing commitment to innovation and global expansion.

A Commitment to Affordability

Zydus’ entry into the US market for this hypertension medication is expected to contribute to increased affordability for patients. By offering a generic alternative, Zydus can potentially help to reduce healthcare costs associated with treating high blood pressure.

Earlier in May 2024, Zydus Lifesciences announced the completion of Enrollment for the Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). The Phase 2 clinical trial will assess the safety and efficacy of Usnoflast in ALS patients.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.